Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) [Phase 2]
Phase 2 MATCH subprotocol F study evaluating crizotinib for cancers with ALK genetic changes. The trial is currently active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance [Phase 2]
Phase 2 clinical trial evaluating busulfan/melphalan conditioning for autologous stem cell transplant with lenalidomide maintenance in multi…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis [Phase 1, Phase 2]
Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in previously untreated symptomatic multiple myeloma or AL amyloidosis. …
-
CLINICAL_TRIALS trial_result · 2022-09-14Clinical Trial Update: Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years [Phase 3]
Phase 3 trial update evaluating treatment for elderly fit patients (65–80) with newly diagnosed multiple myeloma; status ACTIVE_NOT_RECRUITI…
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma [Phase 2]
Phase 2 trial evaluating Carfilzomib, Lenalidomide, and Dexamethasone in Smoldering Multiple Myeloma has completed and results have been pos…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma [Phase 2]
Phase 2 trial evaluating MGTA-145 with plerixafor for mobilization of hematopoietic stem cells in autologous transplantation for multiple my…
-
CLINICAL_TRIALS trial_result · 2022-09-09Clinical Trial Update: Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
A randomized Phase II study in elderly patients with newly diagnosed multiple myeloma is ongoing, with status not provided in the snippet.
-
CLINICAL_TRIALS trial_result · 2022-09-07Clinical Trial Update: Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma [Phase 2]
Phase 2 clinical trial update investigating carfilzomib, cyclophosphamide, and dexamethasone in multiple myeloma.
-
FDA approval · 2022-09-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
The FDA approved Exelan Pharmaceuticals Inc.'s original application for lenalidomide, granting approval of a generic version of the cancer d…
-
CLINICAL_TRIALS trial_result · 2022-09-02Clinical Trial Update: Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT [Phase 2]
Phase 2 clinical trial evaluating matched unrelated donor stem cell transplantation after dose-reduced conditioning in patients with multipl…
-
CLINICAL_TRIALS trial_result · 2022-09-01Clinical Trial Update: Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma [Phase 2]
Phase 2 trial evaluating dendritic cell/myeloma fusion vaccines in combination with nivolumab for relapsed multiple myeloma; study terminate…
-
CLINICAL_TRIALS trial_result · 2022-08-31Clinical Trial Update: Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents [Phase 4]
Phase 4 clinical trial evaluating pneumococcal vaccination in multiple myeloma patients receiving novel therapies has completed.
-
FDA approval · 2022-08-31FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved the original application for Lenalidomide from Alvogen, Inc., enabling a generic version of lenalidomide to enter the market.
-
FDA approval · 2022-08-30FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved lenalidomide as an original application for Mylan Pharmaceuticals Inc., establishing a generic version of lenalidomide.
-
CLINICAL_TRIALS trial_result · 2022-08-22Clinical Trial Update: Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone [Phase 2]
Phase II study evaluating carfilzomib, pomalidomide, and dexamethasone in multiple myeloma patients who relapsed after prior therapy; status…
-
CLINICAL_TRIALS trial_result · 2022-08-22Clinical Trial Update: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM) [Phase 2]
Phase 2 clinical trial update on an anti-BCMA/GPRC5D CAR-T cell therapy for relapsed/refractory multiple myeloma, focusing on safety and eff…
-
CLINICAL_TRIALS trial_result · 2022-08-16Clinical Trial Update: A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients [Phase 2]
Phase 2 trial update on PK, safety, and tolerability of peripheral and central infusion of melflufen in relapsed/refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2022-08-12Clinical Trial Update: Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT [Phase 2]
A Phase 2 trial evaluating re-induction with carfilzomib, lenalidomide, and dexamethasone followed by a second autologous stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2022-08-11Clinical Trial Update: Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating the combination of bortezomib with high-dose melphalan in multiple myeloma has completed enrollment and posted …
-
CLINICAL_TRIALS trial_result · 2022-08-05Clinical Trial Update: HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies [Phase 2]
Phase 2 clinical trial evaluating HLA-compatible related or unrelated donors with CD34+ enriched, T-cell depleted peripheral blood stem cell…
-
CLINICAL_TRIALS trial_result · 2022-08-05Clinical Trial Update: Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 trial evaluating BCMA CAR-T cell therapy in patients with BCMA-positive relapsed or refractory multiple myeloma has completed with r…
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients [Phase 1, Phase 2]
Clinical trial update for FasT CAR-T GC012F in high risk t_NDMM (transplant-eligible and non-durable multiple myeloma) patients across Phase…
-
CLINICAL_TRIALS trial_result · 2022-07-27Clinical Trial Update: A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide [Phase 3]
Phase 3 trial of melphalan flufenamide (melflufen) with dexamethasone or pomalidomide-dexamethasone for relapsed/refractory multiple myeloma…
-
CLINICAL_TRIALS trial_result · 2022-07-27Clinical Trial Update: Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating filanesib (ARRY-520) in combination with pomalidomide and dexamethasone for relapsed/refractory multiple…
-
CLINICAL_TRIALS trial_result · 2022-07-26Clinical Trial Update: LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial update for a quadruplet regimen (carfilzomib, lenalidomide, dexamethasone, and elotuzumab) in relapsed/refractory mul…